USPTO Issues New Guidelines for Subject Matter Eligibility Analysis of Claims Reciting or Involving Laws of Nature/Natural Principles, Natural Phenomena and/or Natural Products
Intellectual Property Alert
March 5, 2014
In 2013 and 2012, the U.S. Supreme Court handed down two important decisions in Association for Molecular Pathology v. Myriad Genetics, Inc. (Myriad) and Mayo Collaborative Services v. Prometheus Laboratories, Inc. (Mayo) regarding patent eligibility. The U.S. Patent and Trademark Office (USPTO) subsequently issued a one-page memorandum in June 2013, providing guidance for dealing with patent applications related to DNAs and promised a more comprehensive guidance.
On March 4, 2014, the USPTO issued a new 19-page guidance memorandum for subject matter eligibility analysis of claims reciting or involving laws of nature/natural principles, natural phenomena and/or natural products (New Guidelines).
Cant post link but search this. Several scenarios provided!! Go Myriad!!!
Winner winner chicken dinner!!!!
USPTO Issues Guidance for Analyzing Subject Matter Eligibility of Claims Reciting Laws of Nature/Natural Principles, Natural Phenomena or Natural Products
3/5/2014byDonald Zuhn | McDonnell Boehnen Hulbert & Berghoff LLP
The golden cross and the death cross
The “cross” refers to two simple moving averages “crossing” over each other. A golden cross is considered a bullish sign; it occurs when the 50-day moving average rises above 200-day moving average. A death cross is considered a bearish sign; it occurs when the 50-day moving average drops below 200-day moving average.
An early mention of moving average crossovers is found in the 1935 book, Profits in the Stock Market, by H. M. Gartley:
“One of the most useful technical phenomena in the determination of major reversals is the major trend moving average. For this purpose, the author prefers to use a 200-day moving aveage, although equally satisfactory results can also be obtained with the use of a 20-30 week moving average applied to weekly charts, or a 4-6 month moving average applied to monthly charts.”
Short interest as if march 1st due out soon. Doubt it us changed. 50 day MA just crossed 200 day. Lift has only begun!!!
February 26, 2014
Dear Community Member:
The mission of the National Comprehensive Cancer Network® (NCCN®), as an alliance of leading cancer centers devoted to patient care, research, and education, is to improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. NCCN supports access, quality, and steps toward more affordable health care for the benefit of all patients with cancer.
At NCCN Member Institutions, people with cancer have access to world-renowned experts who diagnose and treat patients with a broad spectrum of cancers and are recognized for dealing with complex, aggressive, or rare cancers. NCCN Member Institutions provide a multidisciplinary team approach to patient care—a concept and practice they pioneered—and innovative research that contributes significantly to understanding, diagnosing, and treating cancer.
NCCN supports efforts to bring greater transparency and clarity to the plans offered by the federal and state-run health exchanges created under the Affordable Care Act, as well as to the processes for referral of appropriately selected patients to academic cancer centers, so that patients can make informed choices, may receive care by the most appropriate health care team, and have access to state-of-the-art clinical trials.
Robert W. Carlson, MD
Chief Executive Officer
this feels like an inflection point where shorts may wish to consider covering and going long. Could see more favorable court rulings, settlements, CMS price adjustment in the next 30 days.
with 30 percent of new colon cancers to be tested andn a hundred percent of new uterine cancers to be tested, this will open yet another set of flood gates. Firms doing upgrades seem to have their own short agendas currently and seem to be withholding rewarding myriad. In my humble opinion.
March 4, 2014
07:14 EDT MYGN NCCN updates guidelines for hereditary colon cancer testing
Myriad Genetics is pleased to note that the National Comprehensive Cancer Network, or NCCN, has revised its medical guidelines to expand Lynch syndrome screening. Lynch syndrome is the most common cause of hereditary colon cancer in adults. Myriad believes the new guidelines will dramatically expand the number of patients eligible for hereditary colon cancer testing, especially among at-risk asymptomatic patients for whom screening has historically been limited based upon prior guidelines and a lack of insurance reimbursement. Some of the key aspects of the new guidelines include: A recommendation that all patients who meet a five percent or greater risk threshold for Lynch syndrome are appropriate for testing; a recommendation against sequential testing for the five Lynch syndrome genes in lieu of panel testing; an acknowledgement that patients with cancer can proceed directly to sequencing tests without a complicated tissue screening algorithm.
FDA less relevant due to " homebrew" classification. CMS through CLIA much more important. Can't post any links here but Google regulatory approval process and you will see many sources.